Fidia Farmaceutici
Fidia Farmaceutici is a privately held Italian pharmaceutical company founded in 1946 that develops, manufactures and globally distributes hyaluronic acid-based therapeutics across joint care, skin care, eye care, specialty care and health & wellness segments, reaching 120+ countries through subsidiaries and distributors.
- Company typePrivate
- Founded1946
- HeadquartersAbano Terme, Italy
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Fidia Farmaceutici does
Fidia Farmaceutici S.p.A. is a privately held Italian pharmaceutical company founded in 1946 and headquartered in Abano Terme (Padua). It specializes in hyaluronic acid (HA) and its derivatives, producing both high and low-molecular-weight HA through proprietary biotechnological fermentation using GRAS (Generally Recognised As Safe) non-pathogenic organisms. The company operates as a fully integrated pharmaceutical group covering R&D, manufacturing, marketing and global distribution across five therapeutic segments: Joint Care (anchored by the HYMOVIS product line for knee osteoarthritis, including the December 2025 FDA-approved HYMOVIS ONE), Skin Care, Eye Care (expanded via the Altacor acquisition), Specialty Care (including the Oncofid-P Phase III oncology pipeline for bladder cancer, plus Collagenase and HyCar development projects), and Health & Wellness Care (gynaecology, urology, dermatology via Meditrina).
The technology backbone rests on approximately 1,522 patents (1,259 of them HA-specific) and four Italian manufacturing sites: the 330,000 m² Abano Terme headquarters producing vials, ampoules, pre-filled syringes, eye drops, topical products and oral solids (annual capacity of 50M+ injectables, 115M+ topical units, 75M tablets/capsules, 6M pre-filled syringes); the Noto fermentation R&D and API site (AIFA-authorized since 2013); the Paderno Dugnano site for oral and dermal delivery systems (patches, plasters, lip products); and the Monte Giberto site for periocular gauzes and food supplements. Quality systems are certified to ISO 13485, ISO 9001, ISO 14001, ISO 22716, GMP and MDSAP, with US-market products additionally compliant with 21 CFR 211/820.
The business model combines branded pharmaceutical product sales, medical device sales, food supplement distribution (via Meditrina) and contract manufacturing services for third-party APIs, lyophilised vaccines and finished dosage forms. Distribution runs through wholly-owned subsidiaries, local partners and distributors in 120+ countries, supported by the Salesforce Life Sciences Cloud platform adopted in October 2025. FY2025 consolidated turnover reached €538.3 million (+5.5% y/y) with EBITDA of €110.1 million (+12.9% y/y), reflecting an 11% CAGR over 2020-2025 from €319.6 million. Geographic growth was led by Rest of World at +41.1% (including Indonesia and UK acquisitions), Europe at +17.7%, MENA at +15.3% and USA at +8.9%.
Fidia Farmaceutici firmographics
Firmographics- Name
- Fidia Farmaceutici
- Legal name
- Fidia Farmaceutici S.p.A.
- Website
- https://fidiapharma.com
- Company type
- Private
- Founded year
- 1946
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Fidia Farmaceutici is a privately held Italian pharmaceutical company founded in 1946 that develops, manufactures and globally distributes hyaluronic acid-based therapeutics across joint care, skin care, eye care, specialty care and health & wellness segments, reaching 120+ countries through subsidiaries and distributors.
- Ownership category
- akta.pro rank
Fidia Farmaceutici industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Medicinal Chemicals & Botanical Products (2833), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Raw Materials & Critical Reagents Supply Services (media, resins, single-use) (HLAAAKAI)
- akta.pro secondary industry
- Biologics & Biosimilars Distributors (HLAIAJAH)
Keywords
Where Fidia Farmaceutici is headquartered
LocationHeadquarters
- HQ city
- Abano Terme
- HQ country
- Italy
- HQ region
- Europe
Offices6 records
Markets served
Fidia Farmaceutici business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Products: Revenue from medicinal products including hyaluronic acid-based therapeutics for joint care, skin care, eye care, and specialty care. Includes prescription pharmaceuticals and medical devices.
- Medical Devices: Production and sale of medical devices including sterile injectables, topical products, eye drops, dermal delivery systems (patches, plasters, films), and periocular gauzes.
- Food Supplements: Distribution of food supplements in gynaecology, urology and dermatology sectors through Meditrina Pharmaceuticals acquisition.
- Contract Manufacturing: Third-party manufacturing services including production of HA on behalf of third parties, lyophilised vaccines, and various pharmaceutical forms.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels5 records
Fidia Farmaceutici product offering
Product offeringCore offering
Fidia Farmaceutici is a fully integrated Italian pharmaceutical company that develops, manufactures, and globally distributes hyaluronic acid (HA)-based therapeutics across Joint Care (e.g., HYMOVIS for knee osteoarthritis), Skin Care, Eye Care (e.g., Clinitas), Specialty Care (oncology, collagenase), and Health & Wellness segments. The company also offers pharmaceutical contract manufacturing services for injectables, topical products, pre-filled syringes, solid orals, eye drops, medicated plasters, and APIs at its Italian GMP-certified plants.
Product overview
Fidia Farmaceutici is a fully integrated pharmaceutical company founded in 1946, specializing in hyaluronic acid (HA) and its derivatives for therapeutic applications. The company manages the entire product lifecycle from R&D to manufacturing to marketing and sales. Their portfolio spans multiple therapeutic areas including Joint Care (with HYMOVIS® ONE for knee osteoarthritis), Skin Care, Eye Care (including Clinitas from acquired Altacor), Specialty Care (including Oncofid-P for bladder cancer, Collagenase for Dupuytren's contracture, and HyCar for arthritis), and Health & Wellness Care. In addition to proprietary pharmaceutical products, Fidia offers contract manufacturing services for injectables, topical products, pre-filled syringes, solid orals, eye drops, medicated plasters, and food supplements across their four Italian manufacturing sites.
Differentiator
Problem solved
Functional benefit
Brands
- HYMOVIS: HA-based intra-articular therapy for knee osteoarthritis treatment.
- Clinitas
- Oncofid-P
- Fidia Learning Lab
Products and services
- HYMOVIS ONE
- HYMOVIS product line
Quantifiable outcome
- Revenue growth of 5.5% y/y reaching €538.3 million in 2025
- +3 more outcomes
Companies that use Fidia Farmaceutici
Customer profileNamed customers1 record
Segments5 records
Ideal customer profiles2 records
Fidia Farmaceutici technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Fidia Farmaceutici partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and strategic acquisition.
- SalesforcecoreFidia signed on as early adopter of Salesforce Life Sciences Cloud for Customer Engagement, an agent-first AI solution integrating sales, marketing, medical affairs, and reimbursement functions on a single compliant system. Built on Salesforce's Hyperforce infrastructure with HIPAA, GxP, and GDPR compliance. Became generally available on October 11, 2025.
- PfizercorePfizer also signed on as early adopter of Salesforce Life Sciences Cloud alongside Fidia, representing a co-adoption of the AI-powered customer engagement platform.
- Altacor Ltdstrategic acquisitionAcquisition of UK-based specialist ophthalmology company Altacor, marking Fidia's entry into the UK ophthalmology market. Altacor has a growing portfolio including Clinitas dry eye treatment product. This represents a strategic acquisition to expand operational capabilities and strengthen know-how in ophthalmology.
Scale indicators9 records
Recent moves7 records
Expansion highlights6 records
Fidia Farmaceutici competitors and assessment
Company assessmentMarket position
Strengths5 records
Weaknesses4 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Fidia Farmaceutici social profiles
Digital presenceFidia Farmaceutici compliance and trust
Trust signalCompliance12 records
Fidia Farmaceutici financial estimates
Financial estimateRevenue estimate
Valuation estimate
Fidia Farmaceutici leadership team
Management profileNumber of profiles
Profiles6 records
Fidia Farmaceutici subsidiaries and ownership
Company hierarchySubsidiaries2 records
Fidia Farmaceutici funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Fidia Farmaceutici M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Fidia Farmaceutici
What does Fidia Farmaceutici do?
Fidia Farmaceutici is a fully integrated Italian pharmaceutical company that develops, manufactures, and globally distributes hyaluronic acid (HA)-based therapeutics across Joint Care (e.g., HYMOVIS for knee osteoarthritis), Skin Care, Eye Care (e.g., Clinitas), Specialty Care (oncology, collagenase), and Health & Wellness segments. The company also offers pharmaceutical contract manufacturing services for injectables, topical products, pre-filled syringes, solid orals, eye drops, medicated plasters, and APIs at its Italian GMP-certified plants.
Is Fidia Farmaceutici a public or private company?
Fidia Farmaceutici is a private company. It is classified as family owned and is currently operating.
When was Fidia Farmaceutici founded?
Fidia Farmaceutici was founded in 1946. It employs 1,001 to 5,000 people.
Where is Fidia Farmaceutici based?
Fidia Farmaceutici is headquartered in Abano Terme, Italy, in the Europe region.
How does Fidia Farmaceutici make money?
Four revenue lines are on record. Pharmaceutical Products are the primary driver. The others are medical Devices, food Supplements and contract Manufacturing.
Does Fidia Farmaceutici have an API?
No public API is recorded for Fidia Farmaceutici.
What industry is Fidia Farmaceutici in?
Fidia Farmaceutici's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAAAKAI, Raw Materials & Critical Reagents Supply Services (media, resins, single-use), with a secondary code of HLAIAJAH, Biologics & Biosimilars Distributors. Its NAICS code is 3254 and its SIC code is 2834.